INTELLIGENT BIO SOLUTIONS IN (INBS)
US36151G6008 - Common Stock
Overall INBS gets a fundamental rating of 2 out of 10. We evaluated INBS against 193 industry peers in the Health Care Equipment & Supplies industry. INBS has a bad profitability rating. Also its financial health evaluation is rather negative. INBS is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
In the past year INBS has reported negative net income.
INBS had a negative operating cash flow in the past year.
INBS had negative earnings in each of the past 5 years.
In the past 5 years INBS always reported negative operating cash flow.
1.2 Ratios
With a Return On Assets value of -151.80%, INBS is not doing good in the industry: 91.15% of the companies in the same industry are doing better.
With a Return On Equity value of -408.50%, INBS is not doing good in the industry: 86.98% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -151.8% | ||
| ROE | -408.5% | ||
| ROIC | N/A |
ROA(3y)-67.4%
ROA(5y)-128.93%
ROE(3y)-150.67%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
INBS's Gross Margin of 20.67% is on the low side compared to the rest of the industry. INBS is outperformed by 80.21% of its industry peers.
The Profit Margin and Operating Margin are not available for INBS so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.67% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
INBS does not have a ROIC to compare to the WACC, probably because it is not profitable.
INBS has more shares outstanding than it did 1 year ago.
INBS has more shares outstanding than it did 5 years ago.
INBS has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -10.05, we must say that INBS is in the distress zone and has some risk of bankruptcy.
INBS has a worse Altman-Z score (-10.05) than 79.69% of its industry peers.
A Debt/Equity ratio of 0.07 indicates that INBS is not too dependend on debt financing.
INBS has a Debt to Equity ratio (0.07) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -10.05 |
ROIC/WACCN/A
WACC9.65%
2.3 Liquidity
A Current Ratio of 0.57 indicates that INBS may have some problems paying its short term obligations.
Looking at the Current ratio, with a value of 0.57, INBS is doing worse than 95.83% of the companies in the same industry.
INBS has a Quick Ratio of 0.57. This is a bad value and indicates that INBS is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of INBS (0.39) is worse than 96.35% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.39 |
3. Growth
3.1 Past
The earnings per share for INBS have decreased strongly by -403.86% in the last year.
Looking at the last year, INBS shows a very strong growth in Revenue. The Revenue has grown by 164.95%.
Measured over the past years, INBS shows a very strong growth in Revenue. The Revenue has been growing by 87.88% on average per year.
EPS 1Y (TTM)-403.86%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q-350%
Revenue 1Y (TTM)164.95%
Revenue growth 3Y87.88%
Revenue growth 5YN/A
Revenue growth Q2Q112.24%
3.2 Future
Based on estimates for the next years, INBS will show a very strong growth in Earnings Per Share. The EPS will grow by 26.09% on average per year.
The Revenue is expected to grow by 147.63% on average over the next years. This is a very strong growth
EPS Next Y95.32%
EPS Next 2Y40.86%
EPS Next 3Y26.09%
EPS Next 5YN/A
Revenue Next Year141.45%
Revenue Next 2Y159.06%
Revenue Next 3Y147.63%
Revenue Next 5YN/A
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
INBS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for INBS. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
INBS's earnings are expected to grow with 26.09% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.86%
EPS Next 3Y26.09%
5. Dividend
5.1 Amount
No dividends for INBS!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
INTELLIGENT BIO SOLUTIONS IN
NASDAQ:INBS (5/8/2024, 2:50:33 PM)
2.5
-0.39 (-13.49%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap7.10M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -151.8% | ||
| ROE | -408.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.67% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.28
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.07 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.57 | ||
| Quick Ratio | 0.39 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-403.86%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y95.32%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)164.95%
Revenue growth 3Y87.88%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y